nodes	percent_of_prediction	percent_of_DWPC	metapath
Etoricoxib—PTGS2—Triamcinolone—psoriatic arthritis	0.161	0.218	CbGbCtD
Etoricoxib—PTGS2—Betamethasone—psoriatic arthritis	0.138	0.187	CbGbCtD
Etoricoxib—PTGS2—Dexamethasone—psoriatic arthritis	0.0802	0.109	CbGbCtD
Etoricoxib—CYP2C19—Prednisone—psoriatic arthritis	0.0525	0.0712	CbGbCtD
Etoricoxib—CYP2E1—Dexamethasone—psoriatic arthritis	0.0523	0.0709	CbGbCtD
Etoricoxib—CYP3A4—Methylprednisolone—psoriatic arthritis	0.0419	0.0568	CbGbCtD
Etoricoxib—CYP2C19—Dexamethasone—psoriatic arthritis	0.0328	0.0445	CbGbCtD
Etoricoxib—CYP3A4—Triamcinolone—psoriatic arthritis	0.0318	0.0431	CbGbCtD
Etoricoxib—CYP2C9—Dexamethasone—psoriatic arthritis	0.0273	0.037	CbGbCtD
Etoricoxib—CYP3A4—Betamethasone—psoriatic arthritis	0.0273	0.0369	CbGbCtD
Etoricoxib—CYP3A4—Prednisolone—psoriatic arthritis	0.0269	0.0365	CbGbCtD
Etoricoxib—CYP3A4—Prednisone—psoriatic arthritis	0.0254	0.0344	CbGbCtD
Etoricoxib—CYP2D6—Dexamethasone—psoriatic arthritis	0.0249	0.0338	CbGbCtD
Etoricoxib—CYP3A4—Dexamethasone—psoriatic arthritis	0.0159	0.0215	CbGbCtD
Etoricoxib—MAPK14—Atypical NF-kappaB pathway—REL—psoriatic arthritis	0.00203	0.0874	CbGpPWpGaD
Etoricoxib—MAPK14—Nucleotide-binding domain, leucine rich repeat containing receptor (NLR) signaling pathways—MEFV—psoriatic arthritis	0.00132	0.0568	CbGpPWpGaD
Etoricoxib—PTGS2—Fluocinonide—Methylprednisolone—psoriatic arthritis	0.00122	0.159	CbGdCrCtD
Etoricoxib—PTGS2—Fluocinonide—Betamethasone—psoriatic arthritis	0.0012	0.156	CbGdCrCtD
Etoricoxib—PTGS2—Fluocinonide—Dexamethasone—psoriatic arthritis	0.0012	0.156	CbGdCrCtD
Etoricoxib—MAPK14—activated TAK1 mediates p38 MAPK activation—NOD2—psoriatic arthritis	0.00118	0.0506	CbGpPWpGaD
Etoricoxib—PTGS2—Fluocinonide—Triamcinolone—psoriatic arthritis	0.00117	0.153	CbGdCrCtD
Etoricoxib—MAPK14—ATF-2 transcription factor network—IL23A—psoriatic arthritis	0.00116	0.0497	CbGpPWpGaD
Etoricoxib—MAPK14—IL4-mediated signaling events—LTA—psoriatic arthritis	0.00102	0.0437	CbGpPWpGaD
Etoricoxib—PTGS2—Fluticasone Propionate—Methylprednisolone—psoriatic arthritis	0.000736	0.0958	CbGdCrCtD
Etoricoxib—MAPK14—NOD1/2 Signaling Pathway—NOD2—psoriatic arthritis	0.000728	0.0313	CbGpPWpGaD
Etoricoxib—PTGS2—Fluticasone Propionate—Dexamethasone—psoriatic arthritis	0.000725	0.0943	CbGdCrCtD
Etoricoxib—PTGS2—Fluticasone Propionate—Betamethasone—psoriatic arthritis	0.000725	0.0943	CbGdCrCtD
Etoricoxib—PTGS2—Fluticasone Propionate—Triamcinolone—psoriatic arthritis	0.000708	0.0921	CbGdCrCtD
Etoricoxib—MAPK14—Regulation of Androgen receptor activity—REL—psoriatic arthritis	0.000701	0.0301	CbGpPWpGaD
Etoricoxib—MAPK14—Interferon type I signaling pathways—REL—psoriatic arthritis	0.00069	0.0297	CbGpPWpGaD
Etoricoxib—MAPK14—IL-1 signaling pathway—REL—psoriatic arthritis	0.00068	0.0293	CbGpPWpGaD
Etoricoxib—MAPK14—Leptin signaling pathway—REL—psoriatic arthritis	0.000531	0.0228	CbGpPWpGaD
Etoricoxib—MAPK14—Nucleotide-binding domain, leucine rich repeat containing receptor (NLR) signaling pathways—NOD2—psoriatic arthritis	0.000497	0.0214	CbGpPWpGaD
Etoricoxib—MAPK14—IL12-mediated signaling events—IL12B—psoriatic arthritis	0.000497	0.0214	CbGpPWpGaD
Etoricoxib—PTGS2—Overview of nanoparticle effects—CRP—psoriatic arthritis	0.000489	0.021	CbGpPWpGaD
Etoricoxib—MAPK14—TCR Signaling Pathway—REL—psoriatic arthritis	0.000459	0.0197	CbGpPWpGaD
Etoricoxib—MAPK14—MAP kinase activation in TLR cascade—NOD2—psoriatic arthritis	0.000454	0.0195	CbGpPWpGaD
Etoricoxib—MAPK14—Glucocorticoid receptor regulatory network—IL13—psoriatic arthritis	0.000452	0.0194	CbGpPWpGaD
Etoricoxib—MAPK14—B Cell Receptor Signaling Pathway—REL—psoriatic arthritis	0.000432	0.0186	CbGpPWpGaD
Etoricoxib—MAPK14—Signaling mediated by p38-alpha and p38-beta—NOS2—psoriatic arthritis	0.000428	0.0184	CbGpPWpGaD
Etoricoxib—MAPK14—TCR Signaling Pathway—IL17A—psoriatic arthritis	0.000386	0.0166	CbGpPWpGaD
Etoricoxib—MAPK14—IL6-mediated signaling events—CRP—psoriatic arthritis	0.000371	0.016	CbGpPWpGaD
Etoricoxib—MAPK14—TRAF6 Mediated Induction of proinflammatory cytokines—NOD2—psoriatic arthritis	0.000359	0.0154	CbGpPWpGaD
Etoricoxib—MAPK14—MyD88 cascade initiated on plasma membrane—NOD2—psoriatic arthritis	0.000325	0.014	CbGpPWpGaD
Etoricoxib—MAPK14—Toll-like Receptor Signaling Pathway—IL12B—psoriatic arthritis	0.000325	0.014	CbGpPWpGaD
Etoricoxib—Arrhythmia—Betamethasone—psoriatic arthritis	0.000323	0.0014	CcSEcCtD
Etoricoxib—Arrhythmia—Dexamethasone—psoriatic arthritis	0.000323	0.0014	CcSEcCtD
Etoricoxib—Pancreatitis—Methotrexate—psoriatic arthritis	0.000322	0.00139	CcSEcCtD
Etoricoxib—MAPK14—TRAF6 mediated induction of NFkB and MAP kinases upon TLR7/8 or 9 activation—NOD2—psoriatic arthritis	0.000322	0.0138	CbGpPWpGaD
Etoricoxib—Alopecia—Betamethasone—psoriatic arthritis	0.000319	0.00138	CcSEcCtD
Etoricoxib—Alopecia—Dexamethasone—psoriatic arthritis	0.000319	0.00138	CcSEcCtD
Etoricoxib—Angioedema—Triamcinolone—psoriatic arthritis	0.000317	0.00137	CcSEcCtD
Etoricoxib—Haemoglobin—Prednisone—psoriatic arthritis	0.000316	0.00137	CcSEcCtD
Etoricoxib—MAPK14—MyD88 dependent cascade initiated on endosome—NOD2—psoriatic arthritis	0.000316	0.0136	CbGpPWpGaD
Etoricoxib—Angioedema—Methylprednisolone—psoriatic arthritis	0.000316	0.00137	CcSEcCtD
Etoricoxib—Abdominal discomfort—Methotrexate—psoriatic arthritis	0.000315	0.00136	CcSEcCtD
Etoricoxib—Haemorrhage—Prednisone—psoriatic arthritis	0.000315	0.00136	CcSEcCtD
Etoricoxib—Erythema—Betamethasone—psoriatic arthritis	0.000314	0.00136	CcSEcCtD
Etoricoxib—Erythema—Dexamethasone—psoriatic arthritis	0.000314	0.00136	CcSEcCtD
Etoricoxib—Hallucination—Prednisone—psoriatic arthritis	0.000313	0.00135	CcSEcCtD
Etoricoxib—Connective tissue disorder—Prednisone—psoriatic arthritis	0.000309	0.00134	CcSEcCtD
Etoricoxib—Oedema—Prednisolone—psoriatic arthritis	0.000308	0.00133	CcSEcCtD
Etoricoxib—Anaphylactic shock—Prednisolone—psoriatic arthritis	0.000308	0.00133	CcSEcCtD
Etoricoxib—Upper respiratory tract infection—Methotrexate—psoriatic arthritis	0.000305	0.00132	CcSEcCtD
Etoricoxib—MAPK14—Toll Like Receptor 9 (TLR9) Cascade—NOD2—psoriatic arthritis	0.000305	0.0131	CbGpPWpGaD
Etoricoxib—Shock—Prednisolone—psoriatic arthritis	0.000303	0.00131	CcSEcCtD
Etoricoxib—Cough—Triamcinolone—psoriatic arthritis	0.000302	0.00131	CcSEcCtD
Etoricoxib—MAPK14—MyD88:Mal cascade initiated on plasma membrane—NOD2—psoriatic arthritis	0.0003	0.0129	CbGpPWpGaD
Etoricoxib—Photosensitivity reaction—Methotrexate—psoriatic arthritis	0.0003	0.0013	CcSEcCtD
Etoricoxib—Hypertension—Triamcinolone—psoriatic arthritis	0.000299	0.00129	CcSEcCtD
Etoricoxib—Hypertension—Methylprednisolone—psoriatic arthritis	0.000299	0.00129	CcSEcCtD
Etoricoxib—Pneumonia—Methotrexate—psoriatic arthritis	0.000295	0.00127	CcSEcCtD
Etoricoxib—Arthralgia—Methylprednisolone—psoriatic arthritis	0.000294	0.00127	CcSEcCtD
Etoricoxib—Eye disorder—Prednisone—psoriatic arthritis	0.000294	0.00127	CcSEcCtD
Etoricoxib—Anxiety—Methylprednisolone—psoriatic arthritis	0.000293	0.00127	CcSEcCtD
Etoricoxib—Infestation NOS—Methotrexate—psoriatic arthritis	0.000293	0.00127	CcSEcCtD
Etoricoxib—Infestation—Methotrexate—psoriatic arthritis	0.000293	0.00127	CcSEcCtD
Etoricoxib—Unspecified disorder of skin and subcutaneous tissue—Methylprednisolone—psoriatic arthritis	0.000292	0.00127	CcSEcCtD
Etoricoxib—MAPK14—IL12-mediated signaling events—HLA-DRB1—psoriatic arthritis	0.000292	0.0126	CbGpPWpGaD
Etoricoxib—Flushing—Prednisone—psoriatic arthritis	0.000292	0.00126	CcSEcCtD
Etoricoxib—Stevens-Johnson syndrome—Methotrexate—psoriatic arthritis	0.00029	0.00126	CcSEcCtD
Etoricoxib—Dry mouth—Triamcinolone—psoriatic arthritis	0.000289	0.00125	CcSEcCtD
Etoricoxib—Renal failure—Methotrexate—psoriatic arthritis	0.000288	0.00125	CcSEcCtD
Etoricoxib—MAPK14—MyD88-independent cascade—NOD2—psoriatic arthritis	0.000288	0.0124	CbGpPWpGaD
Etoricoxib—Angioedema—Dexamethasone—psoriatic arthritis	0.000287	0.00124	CcSEcCtD
Etoricoxib—Angioedema—Betamethasone—psoriatic arthritis	0.000287	0.00124	CcSEcCtD
Etoricoxib—Stomatitis—Methotrexate—psoriatic arthritis	0.000285	0.00124	CcSEcCtD
Etoricoxib—Angiopathy—Prednisone—psoriatic arthritis	0.000285	0.00124	CcSEcCtD
Etoricoxib—Conjunctivitis—Methotrexate—psoriatic arthritis	0.000285	0.00123	CcSEcCtD
Etoricoxib—Confusional state—Methylprednisolone—psoriatic arthritis	0.000285	0.00123	CcSEcCtD
Etoricoxib—Immune system disorder—Prednisone—psoriatic arthritis	0.000284	0.00123	CcSEcCtD
Etoricoxib—Anaphylactic shock—Triamcinolone—psoriatic arthritis	0.000283	0.00122	CcSEcCtD
Etoricoxib—Oedema—Triamcinolone—psoriatic arthritis	0.000283	0.00122	CcSEcCtD
Etoricoxib—Anaphylactic shock—Methylprednisolone—psoriatic arthritis	0.000282	0.00122	CcSEcCtD
Etoricoxib—MAPK14—ATF-2 transcription factor network—NOS2—psoriatic arthritis	0.000282	0.0121	CbGpPWpGaD
Etoricoxib—Arrhythmia—Prednisone—psoriatic arthritis	0.000281	0.00122	CcSEcCtD
Etoricoxib—Infection—Triamcinolone—psoriatic arthritis	0.000281	0.00122	CcSEcCtD
Etoricoxib—Infection—Methylprednisolone—psoriatic arthritis	0.00028	0.00121	CcSEcCtD
Etoricoxib—Haematuria—Methotrexate—psoriatic arthritis	0.000279	0.00121	CcSEcCtD
Etoricoxib—MAPK14—IL12-mediated signaling events—NOS2—psoriatic arthritis	0.000278	0.012	CbGpPWpGaD
Etoricoxib—Shock—Triamcinolone—psoriatic arthritis	0.000278	0.0012	CcSEcCtD
Etoricoxib—Insomnia—Prednisolone—psoriatic arthritis	0.000278	0.0012	CcSEcCtD
Etoricoxib—Alopecia—Prednisone—psoriatic arthritis	0.000278	0.0012	CcSEcCtD
Etoricoxib—Shock—Methylprednisolone—psoriatic arthritis	0.000278	0.0012	CcSEcCtD
Etoricoxib—Hepatobiliary disease—Methotrexate—psoriatic arthritis	0.000277	0.0012	CcSEcCtD
Etoricoxib—Nervous system disorder—Methylprednisolone—psoriatic arthritis	0.000277	0.0012	CcSEcCtD
Etoricoxib—Epistaxis—Methotrexate—psoriatic arthritis	0.000276	0.0012	CcSEcCtD
Etoricoxib—Mental disorder—Prednisone—psoriatic arthritis	0.000276	0.00119	CcSEcCtD
Etoricoxib—Skin disorder—Methylprednisolone—psoriatic arthritis	0.000274	0.00119	CcSEcCtD
Etoricoxib—Malnutrition—Prednisone—psoriatic arthritis	0.000274	0.00118	CcSEcCtD
Etoricoxib—Erythema—Prednisone—psoriatic arthritis	0.000274	0.00118	CcSEcCtD
Etoricoxib—PTGS2—Signaling mediated by p38-alpha and p38-beta—NOS2—psoriatic arthritis	0.000274	0.0118	CbGpPWpGaD
Etoricoxib—Hypertension—Betamethasone—psoriatic arthritis	0.000271	0.00117	CcSEcCtD
Etoricoxib—Hypertension—Dexamethasone—psoriatic arthritis	0.000271	0.00117	CcSEcCtD
Etoricoxib—Anxiety—Dexamethasone—psoriatic arthritis	0.000267	0.00115	CcSEcCtD
Etoricoxib—Anxiety—Betamethasone—psoriatic arthritis	0.000267	0.00115	CcSEcCtD
Etoricoxib—Haemoglobin—Methotrexate—psoriatic arthritis	0.000264	0.00114	CcSEcCtD
Etoricoxib—Pain—Prednisolone—psoriatic arthritis	0.000263	0.00114	CcSEcCtD
Etoricoxib—Haemorrhage—Methotrexate—psoriatic arthritis	0.000263	0.00114	CcSEcCtD
Etoricoxib—Hepatitis—Methotrexate—psoriatic arthritis	0.000263	0.00114	CcSEcCtD
Etoricoxib—Pharyngitis—Methotrexate—psoriatic arthritis	0.000261	0.00113	CcSEcCtD
Etoricoxib—Urinary tract disorder—Methotrexate—psoriatic arthritis	0.00026	0.00112	CcSEcCtD
Etoricoxib—MAPK14—Activated TLR4 signalling—NOD2—psoriatic arthritis	0.000259	0.0111	CbGpPWpGaD
Etoricoxib—Vision blurred—Prednisone—psoriatic arthritis	0.000258	0.00112	CcSEcCtD
Etoricoxib—MAPK14—AGE/RAGE pathway—NOS2—psoriatic arthritis	0.000258	0.0111	CbGpPWpGaD
Etoricoxib—Urethral disorder—Methotrexate—psoriatic arthritis	0.000258	0.00112	CcSEcCtD
Etoricoxib—Musculoskeletal discomfort—Triamcinolone—psoriatic arthritis	0.000258	0.00112	CcSEcCtD
Etoricoxib—Musculoskeletal discomfort—Methylprednisolone—psoriatic arthritis	0.000257	0.00111	CcSEcCtD
Etoricoxib—Anaphylactic shock—Betamethasone—psoriatic arthritis	0.000257	0.00111	CcSEcCtD
Etoricoxib—Anaphylactic shock—Dexamethasone—psoriatic arthritis	0.000257	0.00111	CcSEcCtD
Etoricoxib—Oedema—Betamethasone—psoriatic arthritis	0.000257	0.00111	CcSEcCtD
Etoricoxib—Oedema—Dexamethasone—psoriatic arthritis	0.000257	0.00111	CcSEcCtD
Etoricoxib—Insomnia—Triamcinolone—psoriatic arthritis	0.000256	0.00111	CcSEcCtD
Etoricoxib—Insomnia—Methylprednisolone—psoriatic arthritis	0.000255	0.0011	CcSEcCtD
Etoricoxib—Infection—Betamethasone—psoriatic arthritis	0.000255	0.0011	CcSEcCtD
Etoricoxib—Infection—Dexamethasone—psoriatic arthritis	0.000255	0.0011	CcSEcCtD
Etoricoxib—MAPK14—Rac1/Pak1/p38/MMP-2 pathway—NOS2—psoriatic arthritis	0.000255	0.011	CbGpPWpGaD
Etoricoxib—MAPK14—Regulation of toll-like receptor signaling pathway—IL12B—psoriatic arthritis	0.000254	0.0109	CbGpPWpGaD
Etoricoxib—Feeling abnormal—Prednisolone—psoriatic arthritis	0.000253	0.0011	CcSEcCtD
Etoricoxib—Visual impairment—Methotrexate—psoriatic arthritis	0.000253	0.0011	CcSEcCtD
Etoricoxib—Anaemia—Prednisone—psoriatic arthritis	0.000253	0.0011	CcSEcCtD
Etoricoxib—Shock—Dexamethasone—psoriatic arthritis	0.000252	0.00109	CcSEcCtD
Etoricoxib—Shock—Betamethasone—psoriatic arthritis	0.000252	0.00109	CcSEcCtD
Etoricoxib—Dyspnoea—Triamcinolone—psoriatic arthritis	0.000252	0.00109	CcSEcCtD
Etoricoxib—Nervous system disorder—Dexamethasone—psoriatic arthritis	0.000252	0.00109	CcSEcCtD
Etoricoxib—Nervous system disorder—Betamethasone—psoriatic arthritis	0.000252	0.00109	CcSEcCtD
Etoricoxib—Agitation—Prednisone—psoriatic arthritis	0.000252	0.00109	CcSEcCtD
Etoricoxib—Thrombocytopenia—Dexamethasone—psoriatic arthritis	0.000251	0.00109	CcSEcCtD
Etoricoxib—Thrombocytopenia—Betamethasone—psoriatic arthritis	0.000251	0.00109	CcSEcCtD
Etoricoxib—Angioedema—Prednisone—psoriatic arthritis	0.00025	0.00108	CcSEcCtD
Etoricoxib—Dyspepsia—Triamcinolone—psoriatic arthritis	0.000249	0.00108	CcSEcCtD
Etoricoxib—Erythema multiforme—Methotrexate—psoriatic arthritis	0.000249	0.00108	CcSEcCtD
Etoricoxib—Dyspepsia—Methylprednisolone—psoriatic arthritis	0.000248	0.00107	CcSEcCtD
Etoricoxib—Eye disorder—Methotrexate—psoriatic arthritis	0.000246	0.00106	CcSEcCtD
Etoricoxib—Tinnitus—Methotrexate—psoriatic arthritis	0.000245	0.00106	CcSEcCtD
Etoricoxib—Anorexia—Dexamethasone—psoriatic arthritis	0.000245	0.00106	CcSEcCtD
Etoricoxib—Anorexia—Betamethasone—psoriatic arthritis	0.000245	0.00106	CcSEcCtD
Etoricoxib—Urticaria—Prednisolone—psoriatic arthritis	0.000244	0.00106	CcSEcCtD
Etoricoxib—Cardiac disorder—Methotrexate—psoriatic arthritis	0.000244	0.00106	CcSEcCtD
Etoricoxib—Fatigue—Triamcinolone—psoriatic arthritis	0.000244	0.00106	CcSEcCtD
Etoricoxib—MAPK14—Toll Like Receptor 4 (TLR4) Cascade—NOD2—psoriatic arthritis	0.000243	0.0105	CbGpPWpGaD
Etoricoxib—Fatigue—Methylprednisolone—psoriatic arthritis	0.000243	0.00105	CcSEcCtD
Etoricoxib—Pain—Triamcinolone—psoriatic arthritis	0.000242	0.00105	CcSEcCtD
Etoricoxib—Angiopathy—Methotrexate—psoriatic arthritis	0.000239	0.00103	CcSEcCtD
Etoricoxib—Immune system disorder—Methotrexate—psoriatic arthritis	0.000237	0.00103	CcSEcCtD
Etoricoxib—Mediastinal disorder—Methotrexate—psoriatic arthritis	0.000237	0.00103	CcSEcCtD
Etoricoxib—Hypertension—Prednisone—psoriatic arthritis	0.000236	0.00102	CcSEcCtD
Etoricoxib—Musculoskeletal discomfort—Dexamethasone—psoriatic arthritis	0.000234	0.00101	CcSEcCtD
Etoricoxib—Musculoskeletal discomfort—Betamethasone—psoriatic arthritis	0.000234	0.00101	CcSEcCtD
Etoricoxib—Arthralgia—Prednisone—psoriatic arthritis	0.000233	0.00101	CcSEcCtD
Etoricoxib—Feeling abnormal—Triamcinolone—psoriatic arthritis	0.000233	0.00101	CcSEcCtD
Etoricoxib—Feeling abnormal—Methylprednisolone—psoriatic arthritis	0.000233	0.00101	CcSEcCtD
Etoricoxib—Anxiety—Prednisone—psoriatic arthritis	0.000232	0.00101	CcSEcCtD
Etoricoxib—Alopecia—Methotrexate—psoriatic arthritis	0.000232	0.00101	CcSEcCtD
Etoricoxib—Insomnia—Dexamethasone—psoriatic arthritis	0.000232	0.001	CcSEcCtD
Etoricoxib—Insomnia—Betamethasone—psoriatic arthritis	0.000232	0.001	CcSEcCtD
Etoricoxib—Unspecified disorder of skin and subcutaneous tissue—Prednisone—psoriatic arthritis	0.000232	0.001	CcSEcCtD
Etoricoxib—Gastrointestinal pain—Methylprednisolone—psoriatic arthritis	0.000231	0.000999	CcSEcCtD
Etoricoxib—Mental disorder—Methotrexate—psoriatic arthritis	0.00023	0.000997	CcSEcCtD
Etoricoxib—Malnutrition—Methotrexate—psoriatic arthritis	0.000229	0.00099	CcSEcCtD
Etoricoxib—Erythema—Methotrexate—psoriatic arthritis	0.000229	0.00099	CcSEcCtD
Etoricoxib—MAPK14—Monoamine Transport—TNF—psoriatic arthritis	0.000228	0.00982	CbGpPWpGaD
Etoricoxib—Hypersensitivity—Prednisolone—psoriatic arthritis	0.000227	0.000981	CcSEcCtD
Etoricoxib—Dyspepsia—Dexamethasone—psoriatic arthritis	0.000226	0.000978	CcSEcCtD
Etoricoxib—Dyspepsia—Betamethasone—psoriatic arthritis	0.000226	0.000978	CcSEcCtD
Etoricoxib—MAPK14—Platelet homeostasis—NOS2—psoriatic arthritis	0.000226	0.0097	CbGpPWpGaD
Etoricoxib—Urticaria—Triamcinolone—psoriatic arthritis	0.000225	0.000972	CcSEcCtD
Etoricoxib—Urticaria—Methylprednisolone—psoriatic arthritis	0.000224	0.00097	CcSEcCtD
Etoricoxib—Dysgeusia—Methotrexate—psoriatic arthritis	0.000224	0.00097	CcSEcCtD
Etoricoxib—Oedema—Prednisone—psoriatic arthritis	0.000223	0.000967	CcSEcCtD
Etoricoxib—Anaphylactic shock—Prednisone—psoriatic arthritis	0.000223	0.000967	CcSEcCtD
Etoricoxib—Abdominal pain—Methylprednisolone—psoriatic arthritis	0.000223	0.000965	CcSEcCtD
Etoricoxib—Decreased appetite—Dexamethasone—psoriatic arthritis	0.000223	0.000965	CcSEcCtD
Etoricoxib—Decreased appetite—Betamethasone—psoriatic arthritis	0.000223	0.000965	CcSEcCtD
Etoricoxib—CYP1A2—Aryl Hydrocarbon Receptor Pathway—IL12B—psoriatic arthritis	0.000222	0.00955	CbGpPWpGaD
Etoricoxib—Infection—Prednisone—psoriatic arthritis	0.000222	0.000961	CcSEcCtD
Etoricoxib—Gastrointestinal disorder—Dexamethasone—psoriatic arthritis	0.000222	0.000959	CcSEcCtD
Etoricoxib—Gastrointestinal disorder—Betamethasone—psoriatic arthritis	0.000222	0.000959	CcSEcCtD
Etoricoxib—PTGS2—Overview of nanoparticle effects—TNF—psoriatic arthritis	0.000221	0.00952	CbGpPWpGaD
Etoricoxib—Fatigue—Dexamethasone—psoriatic arthritis	0.000221	0.000957	CcSEcCtD
Etoricoxib—Fatigue—Betamethasone—psoriatic arthritis	0.000221	0.000957	CcSEcCtD
Etoricoxib—Shock—Prednisone—psoriatic arthritis	0.00022	0.000951	CcSEcCtD
Etoricoxib—Pain—Dexamethasone—psoriatic arthritis	0.000219	0.00095	CcSEcCtD
Etoricoxib—Pain—Betamethasone—psoriatic arthritis	0.000219	0.00095	CcSEcCtD
Etoricoxib—Nervous system disorder—Prednisone—psoriatic arthritis	0.000219	0.000948	CcSEcCtD
Etoricoxib—Skin disorder—Prednisone—psoriatic arthritis	0.000217	0.000939	CcSEcCtD
Etoricoxib—MAPK14—Toll-Like Receptors Cascades—NOD2—psoriatic arthritis	0.000217	0.00932	CbGpPWpGaD
Etoricoxib—Vision blurred—Methotrexate—psoriatic arthritis	0.000216	0.000933	CcSEcCtD
Etoricoxib—Anorexia—Prednisone—psoriatic arthritis	0.000213	0.000922	CcSEcCtD
Etoricoxib—Anaemia—Methotrexate—psoriatic arthritis	0.000212	0.000915	CcSEcCtD
Etoricoxib—Feeling abnormal—Betamethasone—psoriatic arthritis	0.000211	0.000915	CcSEcCtD
Etoricoxib—Feeling abnormal—Dexamethasone—psoriatic arthritis	0.000211	0.000915	CcSEcCtD
Etoricoxib—Gastrointestinal pain—Betamethasone—psoriatic arthritis	0.00021	0.000908	CcSEcCtD
Etoricoxib—Gastrointestinal pain—Dexamethasone—psoriatic arthritis	0.00021	0.000908	CcSEcCtD
Etoricoxib—Hypersensitivity—Triamcinolone—psoriatic arthritis	0.000208	0.000902	CcSEcCtD
Etoricoxib—Hypersensitivity—Methylprednisolone—psoriatic arthritis	0.000208	0.0009	CcSEcCtD
Etoricoxib—Urticaria—Dexamethasone—psoriatic arthritis	0.000204	0.000882	CcSEcCtD
Etoricoxib—Urticaria—Betamethasone—psoriatic arthritis	0.000204	0.000882	CcSEcCtD
Etoricoxib—Musculoskeletal discomfort—Prednisone—psoriatic arthritis	0.000204	0.000881	CcSEcCtD
Etoricoxib—Dizziness—Prednisolone—psoriatic arthritis	0.000203	0.00088	CcSEcCtD
Etoricoxib—Asthenia—Triamcinolone—psoriatic arthritis	0.000203	0.000878	CcSEcCtD
Etoricoxib—Abdominal pain—Betamethasone—psoriatic arthritis	0.000203	0.000878	CcSEcCtD
Etoricoxib—Abdominal pain—Dexamethasone—psoriatic arthritis	0.000203	0.000878	CcSEcCtD
Etoricoxib—Asthenia—Methylprednisolone—psoriatic arthritis	0.000202	0.000876	CcSEcCtD
Etoricoxib—Insomnia—Prednisone—psoriatic arthritis	0.000202	0.000875	CcSEcCtD
Etoricoxib—Pruritus—Triamcinolone—psoriatic arthritis	0.0002	0.000866	CcSEcCtD
Etoricoxib—Cough—Methotrexate—psoriatic arthritis	0.0002	0.000864	CcSEcCtD
Etoricoxib—Pruritus—Methylprednisolone—psoriatic arthritis	0.0002	0.000864	CcSEcCtD
Etoricoxib—MAPK14—Amyotrophic lateral sclerosis (ALS)—TNF—psoriatic arthritis	0.000199	0.00856	CbGpPWpGaD
Etoricoxib—Dyspepsia—Prednisone—psoriatic arthritis	0.000197	0.000851	CcSEcCtD
Etoricoxib—Chest pain—Methotrexate—psoriatic arthritis	0.000195	0.000843	CcSEcCtD
Etoricoxib—Arthralgia—Methotrexate—psoriatic arthritis	0.000195	0.000843	CcSEcCtD
Etoricoxib—Decreased appetite—Prednisone—psoriatic arthritis	0.000194	0.000841	CcSEcCtD
Etoricoxib—Rash—Prednisolone—psoriatic arthritis	0.000194	0.000839	CcSEcCtD
Etoricoxib—Dermatitis—Prednisolone—psoriatic arthritis	0.000194	0.000838	CcSEcCtD
Etoricoxib—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—psoriatic arthritis	0.000193	0.000837	CcSEcCtD
Etoricoxib—Diarrhoea—Methylprednisolone—psoriatic arthritis	0.000193	0.000836	CcSEcCtD
Etoricoxib—Fatigue—Prednisone—psoriatic arthritis	0.000193	0.000834	CcSEcCtD
Etoricoxib—Headache—Prednisolone—psoriatic arthritis	0.000193	0.000834	CcSEcCtD
Etoricoxib—Constipation—Prednisone—psoriatic arthritis	0.000191	0.000827	CcSEcCtD
Etoricoxib—Confusional state—Methotrexate—psoriatic arthritis	0.000188	0.000815	CcSEcCtD
Etoricoxib—Dizziness—Triamcinolone—psoriatic arthritis	0.000187	0.000809	CcSEcCtD
Etoricoxib—Anaphylactic shock—Methotrexate—psoriatic arthritis	0.000187	0.000808	CcSEcCtD
Etoricoxib—Dizziness—Methylprednisolone—psoriatic arthritis	0.000187	0.000808	CcSEcCtD
Etoricoxib—MAPK14—Innate Immune System—MEFV—psoriatic arthritis	0.000187	0.00802	CbGpPWpGaD
Etoricoxib—Infection—Methotrexate—psoriatic arthritis	0.000186	0.000803	CcSEcCtD
Etoricoxib—Feeling abnormal—Prednisone—psoriatic arthritis	0.000184	0.000797	CcSEcCtD
Etoricoxib—Asthenia—Dexamethasone—psoriatic arthritis	0.000184	0.000797	CcSEcCtD
Etoricoxib—Asthenia—Betamethasone—psoriatic arthritis	0.000184	0.000797	CcSEcCtD
Etoricoxib—MAPK14—TWEAK Signaling Pathway—TNF—psoriatic arthritis	0.000184	0.0079	CbGpPWpGaD
Etoricoxib—Nervous system disorder—Methotrexate—psoriatic arthritis	0.000183	0.000793	CcSEcCtD
Etoricoxib—Thrombocytopenia—Methotrexate—psoriatic arthritis	0.000183	0.000791	CcSEcCtD
Etoricoxib—Gastrointestinal pain—Prednisone—psoriatic arthritis	0.000183	0.000791	CcSEcCtD
Etoricoxib—Nausea—Prednisolone—psoriatic arthritis	0.000183	0.000791	CcSEcCtD
Etoricoxib—Pruritus—Betamethasone—psoriatic arthritis	0.000182	0.000786	CcSEcCtD
Etoricoxib—Pruritus—Dexamethasone—psoriatic arthritis	0.000182	0.000786	CcSEcCtD
Etoricoxib—Skin disorder—Methotrexate—psoriatic arthritis	0.000181	0.000785	CcSEcCtD
Etoricoxib—Vomiting—Triamcinolone—psoriatic arthritis	0.00018	0.000778	CcSEcCtD
Etoricoxib—Vomiting—Methylprednisolone—psoriatic arthritis	0.000179	0.000776	CcSEcCtD
Etoricoxib—Rash—Triamcinolone—psoriatic arthritis	0.000178	0.000772	CcSEcCtD
Etoricoxib—Dermatitis—Triamcinolone—psoriatic arthritis	0.000178	0.000771	CcSEcCtD
Etoricoxib—Anorexia—Methotrexate—psoriatic arthritis	0.000178	0.00077	CcSEcCtD
Etoricoxib—Rash—Methylprednisolone—psoriatic arthritis	0.000178	0.00077	CcSEcCtD
Etoricoxib—Dermatitis—Methylprednisolone—psoriatic arthritis	0.000178	0.000769	CcSEcCtD
Etoricoxib—Urticaria—Prednisone—psoriatic arthritis	0.000178	0.000768	CcSEcCtD
Etoricoxib—Headache—Triamcinolone—psoriatic arthritis	0.000177	0.000767	CcSEcCtD
Etoricoxib—Headache—Methylprednisolone—psoriatic arthritis	0.000177	0.000765	CcSEcCtD
Etoricoxib—Abdominal pain—Prednisone—psoriatic arthritis	0.000177	0.000765	CcSEcCtD
Etoricoxib—Diarrhoea—Dexamethasone—psoriatic arthritis	0.000176	0.00076	CcSEcCtD
Etoricoxib—Diarrhoea—Betamethasone—psoriatic arthritis	0.000176	0.00076	CcSEcCtD
Etoricoxib—Musculoskeletal discomfort—Methotrexate—psoriatic arthritis	0.00017	0.000736	CcSEcCtD
Etoricoxib—Dizziness—Betamethasone—psoriatic arthritis	0.00017	0.000734	CcSEcCtD
Etoricoxib—Dizziness—Dexamethasone—psoriatic arthritis	0.00017	0.000734	CcSEcCtD
Etoricoxib—Insomnia—Methotrexate—psoriatic arthritis	0.000169	0.000731	CcSEcCtD
Etoricoxib—Nausea—Triamcinolone—psoriatic arthritis	0.000168	0.000727	CcSEcCtD
Etoricoxib—Nausea—Methylprednisolone—psoriatic arthritis	0.000168	0.000725	CcSEcCtD
Etoricoxib—Dyspnoea—Methotrexate—psoriatic arthritis	0.000167	0.000721	CcSEcCtD
Etoricoxib—Somnolence—Methotrexate—psoriatic arthritis	0.000166	0.000719	CcSEcCtD
Etoricoxib—Hypersensitivity—Prednisone—psoriatic arthritis	0.000165	0.000713	CcSEcCtD
Etoricoxib—Dyspepsia—Methotrexate—psoriatic arthritis	0.000164	0.000711	CcSEcCtD
Etoricoxib—Vomiting—Betamethasone—psoriatic arthritis	0.000163	0.000706	CcSEcCtD
Etoricoxib—Vomiting—Dexamethasone—psoriatic arthritis	0.000163	0.000706	CcSEcCtD
Etoricoxib—Decreased appetite—Methotrexate—psoriatic arthritis	0.000162	0.000703	CcSEcCtD
Etoricoxib—Rash—Betamethasone—psoriatic arthritis	0.000162	0.0007	CcSEcCtD
Etoricoxib—Rash—Dexamethasone—psoriatic arthritis	0.000162	0.0007	CcSEcCtD
Etoricoxib—Dermatitis—Betamethasone—psoriatic arthritis	0.000162	0.0007	CcSEcCtD
Etoricoxib—Dermatitis—Dexamethasone—psoriatic arthritis	0.000162	0.0007	CcSEcCtD
Etoricoxib—Gastrointestinal disorder—Methotrexate—psoriatic arthritis	0.000161	0.000698	CcSEcCtD
Etoricoxib—Fatigue—Methotrexate—psoriatic arthritis	0.000161	0.000697	CcSEcCtD
Etoricoxib—Headache—Dexamethasone—psoriatic arthritis	0.000161	0.000696	CcSEcCtD
Etoricoxib—Headache—Betamethasone—psoriatic arthritis	0.000161	0.000696	CcSEcCtD
Etoricoxib—Asthenia—Prednisone—psoriatic arthritis	0.00016	0.000694	CcSEcCtD
Etoricoxib—MAPK14—Angiopoietin receptor Tie2-mediated signaling—TNF—psoriatic arthritis	0.00016	0.00687	CbGpPWpGaD
Etoricoxib—Pain—Methotrexate—psoriatic arthritis	0.00016	0.000691	CcSEcCtD
Etoricoxib—Pruritus—Prednisone—psoriatic arthritis	0.000158	0.000684	CcSEcCtD
Etoricoxib—Feeling abnormal—Methotrexate—psoriatic arthritis	0.000154	0.000666	CcSEcCtD
Etoricoxib—Diarrhoea—Prednisone—psoriatic arthritis	0.000153	0.000662	CcSEcCtD
Etoricoxib—Gastrointestinal pain—Methotrexate—psoriatic arthritis	0.000153	0.000661	CcSEcCtD
Etoricoxib—Nausea—Betamethasone—psoriatic arthritis	0.000152	0.00066	CcSEcCtD
Etoricoxib—Nausea—Dexamethasone—psoriatic arthritis	0.000152	0.00066	CcSEcCtD
Etoricoxib—Urticaria—Methotrexate—psoriatic arthritis	0.000148	0.000642	CcSEcCtD
Etoricoxib—MAPK14—Cardiac Hypertrophic Response—TNF—psoriatic arthritis	0.000148	0.00637	CbGpPWpGaD
Etoricoxib—Dizziness—Prednisone—psoriatic arthritis	0.000148	0.00064	CcSEcCtD
Etoricoxib—Abdominal pain—Methotrexate—psoriatic arthritis	0.000148	0.000639	CcSEcCtD
Etoricoxib—PTGS2—Selenium Micronutrient Network—CRP—psoriatic arthritis	0.000144	0.00617	CbGpPWpGaD
Etoricoxib—Vomiting—Prednisone—psoriatic arthritis	0.000142	0.000615	CcSEcCtD
Etoricoxib—Rash—Prednisone—psoriatic arthritis	0.000141	0.00061	CcSEcCtD
Etoricoxib—Dermatitis—Prednisone—psoriatic arthritis	0.000141	0.000609	CcSEcCtD
Etoricoxib—Headache—Prednisone—psoriatic arthritis	0.00014	0.000606	CcSEcCtD
Etoricoxib—Hypersensitivity—Methotrexate—psoriatic arthritis	0.000138	0.000595	CcSEcCtD
Etoricoxib—Asthenia—Methotrexate—psoriatic arthritis	0.000134	0.00058	CcSEcCtD
Etoricoxib—Nausea—Prednisone—psoriatic arthritis	0.000133	0.000574	CcSEcCtD
Etoricoxib—Pruritus—Methotrexate—psoriatic arthritis	0.000132	0.000572	CcSEcCtD
Etoricoxib—Diarrhoea—Methotrexate—psoriatic arthritis	0.000128	0.000553	CcSEcCtD
Etoricoxib—Dizziness—Methotrexate—psoriatic arthritis	0.000124	0.000534	CcSEcCtD
Etoricoxib—Vomiting—Methotrexate—psoriatic arthritis	0.000119	0.000514	CcSEcCtD
Etoricoxib—Rash—Methotrexate—psoriatic arthritis	0.000118	0.00051	CcSEcCtD
Etoricoxib—Dermatitis—Methotrexate—psoriatic arthritis	0.000118	0.000509	CcSEcCtD
Etoricoxib—Headache—Methotrexate—psoriatic arthritis	0.000117	0.000506	CcSEcCtD
Etoricoxib—Nausea—Methotrexate—psoriatic arthritis	0.000111	0.00048	CcSEcCtD
Etoricoxib—PTGS2—Aryl Hydrocarbon Receptor—TNF—psoriatic arthritis	0.000109	0.00469	CbGpPWpGaD
Etoricoxib—MAPK14—Immune System—MEFV—psoriatic arthritis	0.000109	0.00467	CbGpPWpGaD
Etoricoxib—MAPK14—MicroRNAs in cardiomyocyte hypertrophy—TNF—psoriatic arthritis	0.000106	0.00454	CbGpPWpGaD
Etoricoxib—PTGS2—Spinal Cord Injury—NOS2—psoriatic arthritis	0.000104	0.00445	CbGpPWpGaD
Etoricoxib—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—TNF—psoriatic arthritis	0.000102	0.00439	CbGpPWpGaD
Etoricoxib—MAPK14—Innate Immune System—HLA-C—psoriatic arthritis	9.55e-05	0.00411	CbGpPWpGaD
Etoricoxib—MAPK14—Toll-like Receptor Signaling Pathway—TNF—psoriatic arthritis	9.04e-05	0.00389	CbGpPWpGaD
Etoricoxib—MAPK14—Regulation of toll-like receptor signaling pathway—TNF—psoriatic arthritis	7.06e-05	0.00303	CbGpPWpGaD
Etoricoxib—MAPK14—Innate Immune System—NOD2—psoriatic arthritis	7.02e-05	0.00302	CbGpPWpGaD
Etoricoxib—PTGS2—Selenium Micronutrient Network—TNF—psoriatic arthritis	6.5e-05	0.00279	CbGpPWpGaD
Etoricoxib—CYP1A2—Aryl Hydrocarbon Receptor Pathway—TNF—psoriatic arthritis	6.18e-05	0.00266	CbGpPWpGaD
Etoricoxib—CYP1A2—Aryl Hydrocarbon Receptor—TNF—psoriatic arthritis	6.18e-05	0.00266	CbGpPWpGaD
Etoricoxib—MAPK14—MAPK Signaling Pathway—TNF—psoriatic arthritis	6.06e-05	0.00261	CbGpPWpGaD
Etoricoxib—MAPK14—Immune System—REL—psoriatic arthritis	6.04e-05	0.0026	CbGpPWpGaD
Etoricoxib—MAPK14—Innate Immune System—HLA-B—psoriatic arthritis	5.65e-05	0.00243	CbGpPWpGaD
Etoricoxib—MAPK14—Immune System—HLA-C—psoriatic arthritis	5.56e-05	0.00239	CbGpPWpGaD
Etoricoxib—MAPK14—Integrated Pancreatic Cancer Pathway—TNF—psoriatic arthritis	5.47e-05	0.00235	CbGpPWpGaD
Etoricoxib—PTGS2—Spinal Cord Injury—TNF—psoriatic arthritis	5.14e-05	0.00221	CbGpPWpGaD
Etoricoxib—MAPK14—Hemostasis—NOS2—psoriatic arthritis	5.06e-05	0.00217	CbGpPWpGaD
Etoricoxib—MAPK14—Innate Immune System—CRP—psoriatic arthritis	4.99e-05	0.00215	CbGpPWpGaD
Etoricoxib—MAPK14—Immune System—NOD2—psoriatic arthritis	4.09e-05	0.00176	CbGpPWpGaD
Etoricoxib—PTGS2—Integrated Pancreatic Cancer Pathway—TNF—psoriatic arthritis	3.5e-05	0.0015	CbGpPWpGaD
Etoricoxib—MAPK14—Immune System—HLA-B—psoriatic arthritis	3.29e-05	0.00141	CbGpPWpGaD
Etoricoxib—MAPK14—Immune System—CRP—psoriatic arthritis	2.91e-05	0.00125	CbGpPWpGaD
Etoricoxib—MAPK14—Immune System—HLA-DRB1—psoriatic arthritis	2.78e-05	0.0012	CbGpPWpGaD
Etoricoxib—MAPK14—Developmental Biology—TNF—psoriatic arthritis	2.56e-05	0.0011	CbGpPWpGaD
Etoricoxib—PTGS2—Disease—NOS2—psoriatic arthritis	1.56e-05	0.000672	CbGpPWpGaD
